glp-1 agonists and sglt2 inhibitors combination Cardiorenal Protection: Potential of Receptor in the Treatment of Type 2 Diabetes | Diabetes Therapy Assessing the proportion of patients
Description
Her extensive nursing ba...
Guirguis says combination treatments such as this could offer additive or synergistic effects meaning that patients have a better chance of responding to at least one of the mechanisms and could experience fewer GI side effects as a result of the dual approach
A 26-Week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin
GLP-1 Receptor Agonist Market (2026 - 2033)
After PS matching, the mean diabetes duration in the GLP-1 RA group was 6.54.5 years, and the mean duration of GLP-1 RA treatment was 2.43.0 years
doi: 10.1007/s00125-004-1380-0 27 DruckerDJ
